NCT02326935View on ClinicalTrials.gov

Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

May 18, 2018

Study Completion Date

May 18, 2018

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

Autologous adipose derived mesenchymal cells

Autologous adipose derived mesenchymal cells, 150M cells deployed via two (2) treatments via intravenous injection.

Trial Locations (1)

KY1-1205

The Da Vinci Center, George Town

Sponsors
All Listed Sponsors
lead

American CryoStem Corporation

INDUSTRY

NCT02326935 - Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis | Biotech Hunter | Biotech Hunter